Physician profile
Ryan T Borrowman
NPI 1487001442
$2,084.10
in general payments reported to CMS, 2019-2025
29 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $611 · 2022: $491 · 2023: $451 · 2024: $223 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $505.09 | 2021-2025 | |
| Pfizer INC. | $282.80 | 2021-2025 | |
| Lilly USA, LLC | $157.74 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $152.19 | 2022 | |
| Janssen Pharmaceuticals, INC | $128.51 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.23 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Astellas Pharma US INC | $84.99 | 2022 | |
| Indivior INC. | $62.88 | 2025 | Sublocade |
| Astrazeneca Pharmaceuticals LP | $58.11 | 2021-2023 | Farxiga |
| Amgen INC. | $48.69 | 2021-2024 | Repatha, Otezla |
| Lucid Diagnostics INC. | $43.71 | 2023 | |
| Exact Sciences Corporation | $43.50 | 2025 | The Cologuard Plus Collection Kit |
| Lundbeck LLC | $40.12 | 2024 | Vyepti, Rexulti |
| Biohaven Pharmaceuticals, INC. | $40.09 | 2021 | |
| Nevro Corp. | $36.26 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $35.49 | 2023-2024 | Quviviq |
| Boston Scientific Corporation | $35.26 | 2022 | |
| Medtronic, INC. | $29.19 | 2022-2023 | Intellis Adaptivestim |
| Axsome Therapeutics, INC. | $25.60 | 2023 | Auvelity |
| Radius Health, INC. | $20.68 | 2025 | Tymlos |
| Abiomed | $19.75 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.04 | 2025 | |
| Halozyme INC | $17.61 | 2023 | |
| Allergan, INC. | $15.51 | 2021 | |
| Antares Pharma, INC. | $15.38 | 2025 | Xyosted |
| Amarin Pharma, INC. | $14.50 | 2021 | |
| Merck Sharp & Dohme LLC | $14.32 | 2021 | |
| Glaxosmithkline, LLC. | $12.15 | 2021 | |
| Novo Nordisk INC | $11.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Borrowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.